Clinical Trial Update: A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma [Phase 3]

View source ↗

Summary

Phase 3 trial update showing completion of a study comparing ABP-206, Amgen's nivolumab biosimilar, with Opdivo (nivolumab) in patients with resected melanoma t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• ABP-206 (nivolumab biosimilar)
• OPDIVO (nivolumab)

Snippet

Sponsor: Amgen | Conditions: Melanoma | Phase 3 | Status: COMPLETED